Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Imnovid (pomalidomide) - Important Safety Information from Celgene Europe Limited as approved by the HPRA (April 2016)
Notice type:
3rd Party Publications
Date:
26/04/2016
Problem Or Issue:
Important Safety Information communication from Celgene Europe Limited on new important advice - hepatitis B virus status to be established before initiating treatment with Imnovid (pomalidomide).
Important Safety Information - Imnovid (pomalidomide)
« Back
Date Printed: 26/04/2024